Guha Udayan 4

What Happened
Udayan Guha, Chief Medical Officer of NextCure, was granted 14,670 derivative shares (reported as an award/acquisition) on January 30, 2026. The filing shows an acquisition price of $0.00 and a total reported value of $0, indicating these are equity awards (options or restricted-equity units) rather than an open-market purchase.

Key Details

• Transaction date: January 30, 2026. Report filed February 3, 2026 (appears to be one business day after the typical two-business-day Form 4 deadline).
• Security: 14,670 derivative shares granted; price reported $0.00; total reported value $0.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote: One-fourth of the option vests on January 30, 2027; the remainder vests in 36 monthly installments beginning February 28, 2027 (standard 4-year schedule with 1-year cliff).
• Transaction type: Award/Grant of derivative securities (code A) — not a sale or open-market purchase.

Context
This is a compensation grant subject to time-based vesting and does not represent an immediate purchase or sale of shares. Such awards are commonly used to retain and incentivize executives; they only convert into owned stock as they vest (and may require exercise if structured as options). The filing timing should be noted by investors because Form 4s are normally due within two business days of the transaction.